Encouraging results of preserving ovarian function after allo-HSCT with RIC

Abstract

Allogeneic hematopoietic SCT (HSCT) is an established method of treating patients with high-risk hematological malignancies. However, intensified conditioning regimen before transplantation results in serious complications for long-term survivors such as growth deceleration, hypogonadism, thyroid dysfunctions, cardiovascular or lung complications and secondary cancers.1 More than 80% of long-term female survivors demonstrate ovarian failure.2, 3 Practices such as TBI with ovarian shielding, and collection of mature oocytes before gonadotoxic therapy4, 5 have been used to preserve ovarian function.